Impact of liposomal bupivacaine parasternal block combined with rectus sheath block on postoperative pain in patients undergoing sternotomy for cardiac surgery: a randomized controlled trial Authors: Yangsi Huang, Mei Hong, Qi Mao, Dongke Liang, Guofeng Liu, Mingxin Huang, Haiping Zhong, Yizhi Lu, Yu Zhong, Yanhua Chen Published: 2026 ABSTRACT ObjectiveTo compare the effects of liposomal bupivacaine and ropivacaine for ultrasound-guided parasternal block combined with rectus sheath block (PSB + RSB) on acute and chronic postoperative pain in patients undergoing cardiac sternotomy, so as to provide an evidence-based basis for optimizing the multimodal analgesia regimen for such surgeries.MethodsA total of 90 patients scheduled for elective median sternotomy cardiac and great vessel surgery at the Institute of Cardiovascular Diseases, The First Affiliated Hospital of Guangxi Medical University from April 2024 to February 2025 were enrolled. They were divided into the liposomal bupivacaine group (group LB, n=45) and the ropivacaine group (group ROP, n=45) using the random number table method. After endotracheal intubation under general anesthesia, group LB was given 40 mL of 266 mg liposomal bupivacaine injection for bilateral PSB+RSB, while group ROP was administered 40 mL of 0.375% ropivacaine injection for the same block regimen.The following outcomes were recorded at different postoperative time points: cumulative consumption of analgesic drugs (calculated as morphine milligram equivalents, MMEs), scores of Numeric Rating Scale (NRS, 0-10 points) for pain assessment, scores of Quality of Recovery-15 (QoR-15) scale, and the incidence of adverse events.ResultsA total of 88 patients completed the study (2 patients in group LB were excluded due to surgical duration exceeding 8 hours). At 24 h and 48 h after the first postoperative awakening, the cumulative MMEs consumption in group LB was significantly lower than that in group ROP [55.30(47.80,62.10) vs 68.00(48.40,80.00) mg, 76.30(68.80, 83.10) mg vs 86.00(63.40,119.60), all P < 0.05]. At 4 h and 12 h post-extubation, the activity-related NRS scores in group LB were significantly lower than those in group ROP [ 2.00(2.00, 2.00) points vs 2.00(2.00,3.00) points, 2.00(2.00,3.00) points vs 3.00(2.00,4.00) points, all P < 0.05]. At 24 h, 48 h and 72 h post-extubation, the QoR-15 scores in group LB were significantly higher than those in group ROP [(85.4±11.78) points vs (74.7±9.89) points, (91.6±10.4) points vs (86.8±8.6) points, (107.1±9.87) points vs (100.0±9.15) points, all P < 0.05]. The incidence of postoperative nausea and vomiting in group LB (16.3%, 7/43) was significantly higher than that in group ROP (2.2%, 1/45) (P < 0.05). There were no significant differences between the two groups in postoperative endotracheal extubation time, ICU stay time, hospital stay, and the incidence of chronic postsurgical pain (CPSP) at 3 months after surgery .ConclusionThe use of liposomal bupivacaine for PSB+RSB block in patients undergoing cardiac sternotomy can significantly reduce postoperative analgesic consumption, optimize early analgesic effect, and improve postoperative recovery quality. However, attention should be paid to the risk of nausea and vomiting, and individualized selection should be made after balancing the benefits and risks in clinical application.Trial registrationTrial registration:This trial was registered in the Chinese Clinical Trial Registry (ChiCTR2400084078) on May 10, 2024 (https://www.chictr.org.cn/).Supplementary InformationThe online version contains supplementary material available at 10.1186/s12871-026-03903-y. Introduction Cardiovascular diseases have become the leading cause of death worldwide. In 2021, the number of deaths due to cardiovascular diseases globally reached 20.5 million, and the proportion of deaths related to cardiovascular diseases among urban and rural residents in China was as high as 40% [1]. Median sternotomy serves as the mainstay treatment for complex cardiovascular diseases, yet both acute and chronic postoperative pain remain highly prevalent [2]. Its mechanism involves multiple aspects such as tissue damage caused by surgical trauma, mechanical stimulation of drainage tubes, destruction of chest wall mechanical stability, and neural sensitization [3, 4]. Traditional postoperative analgesic regimens have obvious limitations: as classic analgesics, opioids are prone to cause adverse reactions such as respiratory depression, nausea and vomiting, and intestinal paralysis [5], drug-induced inhibition of the brainstem respiratory center causes reduced respiratory rate and tidal volume, which may prolong mechanical ventilation and elevate pulmonary complication risk [6], and may increase the risk of chronic postsurgical pain (CPSP) by inducing pain sensitization [7]; although thoracic epidural analgesia (TEA) has a definite analgesic effect, it is difficult to be used as a routine regimen in cardiac surgery because it may increase the risks of epidural hematoma and infection [8]. Under the concept of multimodal analgesia, regional block technology has become a research focus due to its precise analgesia and minimal impact on systemic hemodynamics. Among them, parasternal block (PSB) can effectively cover the anterior branches of the intercostal nerves from T2 to T6 dermatomes [9], and rectus sheath block (RSB) can block the anterior cutaneous branches of the intercostal nerves from T6 to T11 [10]. The combination of the two (PSB + RSB) can fully cover the pain areas related to sternotomy incisions and thoracic drainage tubes, and has been proven to be an effective analgesic method for sternotomy . Ropivacaine is a widely used long-acting amide local anesthetic, yet its duration of action remains comparatively short; a single block typically provides analgesia for no more than 12 h. This duration is often insufficient to cover the peak pain period occurring 24 to 48 h after sternotomy [11]. Liposomal bupivacaine represents a newer sustained-release formulation. Through its phospholipid bilayer encapsulation technology, it achieves a three-phase release pattern consisting of burst release, a lag phase, and secondary release. This characteristic allows it to deliver sustained analgesia for up to 72 h. Additionally, it results in a lower peak plasma concentration of free drug, which is associated with reduced risks of central nervous system and cardiovascular toxicity [12, 13]. To compare the analgesic effect and safety of liposomal bupivacaine versus ropivacaine in ultrasound-guided parasternal plus rectus sheath block (PSB + RSB), this study was conducted as a prospective randomized controlled trial (RCT). Its aim is to investigate the effect of liposomal bupivacaine on postoperative pain in patients undergoing cardiac surgery and provide high-level evidence-based medical evidence to support the optimization of analgesic regimens for patients. Methods This study was approved by the Ethics Committee of The First Affiliated Hospital of Guangxi Medical University (Approval No.: 2023-K255-01) and registered at the Chinese Clinical Trial Registry (Registration No.: ChiCTR2400084078). All patients signed written informed consent forms.This study was conducted and reported in accordance with the CONSORT 2010 statement. Participants Patients aged 18–65 years, who were scheduled for elective median sternotomy for cardiac surgery at The First Affiliated Hospital of Guangxi Medical University and had an American Society of Anesthesiologists (ASA) physical status classification of I–III, were recruited for the study. Exclusion criteria included patients with severe cardiopulmonary, hepatic, or renal dysfunction; those with chest deformities preventing nerve block; individuals with a history of two or more previous thoracotomies; a body mass index (BMI) of ≥ 28 kg/m²; those with alcohol or opioid addiction; patients allergic to local anesthetics; those unwilling to participate; and patients with severe neurological or psychiatric disorders. Additionally, patients were excluded if they developed severe surgical or anesthetic complications during the perioperative period; were unable to cooperate with the Numeric Rating Scale (NRS) and Quality of Recovery-15 (QoR-15) scoring; required reoperation before discharge or postoperatively; underwent operations lasting more than 7 h; did not undergo cardiopulmonary bypass; or experienced serious adverse reactions, significant physiological changes, or other unexpected events making it inappropriate to continue in the study. Randomization and blinding An initial value was randomly selected from a random number table, and 90 consecutive numbers were extracted in a fixed direction. Every 10 numbers formed a block. Within each block, the 5 smaller numbers were assigned to the LB group (liposomal bupivacaine group), and the 5 larger numbers were assigned to the ROP group (ropivacaine group). The randomization allocation table was sealed and signed by the investigator. Each envelope was labeled with the corresponding sequence number and stored under strict confidentiality. An independent researcher, who was not involved in participant recruitment, treatment administration, or data analysis, generated the randomization sequence. Each participant was then assigned a unique identifier corresponding to their group allocation based on this list. The allocation schedule was sealed in sequentially numbered, opaque, and tamper-evident envelopes to ensure confidentiality and secure storage. The day before surgery, each participant’s eligibility was confirmed, and written informed consent was obtained. On the day of surgery, an individual not involved in the study procedures opened the corresponding envelope to reveal the assigned anesthetic plan. An independent statistician regularly audited the entire randomization and allocation concealment process to ensure strict adherence to the study protocol. Anesthesia management, postoperative data collection, and statistical analysis were performed by personnel blinded to group assignment. Anesthetic preparation Routine preoperative preparation included 12 h of fasting and 4 h of fluid restriction. Upon entering the operating room on the day of surgery, continuous monitoring was initiated, encompassing electrocardiogram (ECG), heart rate (HR), peripheral oxygen saturation (SpO₂), bispectral index (BIS), and mean arterial pressure (MAP). Peripheral venous access was first established. Subsequently, a radial artery catheter was inserted for invasive arterial pressure monitoring, and a catheter was placed in the right internal jugular vein to enable fluid resuscitation and intravenous drug administration. Anesthetic method Anesthesia induction was performed as follows: ciprofol (0.4 mg/kg), sufentanil (1 µg/kg), and rocuronium (0.6 mg/kg) were administered intravenously in sequence. Once the BIS value decreased to below 60, endotracheal intubation was performed, followed by connection to a ventilator for assisted ventilation. Anesthesia maintenance was performed as follows: continuous intravenous infusion of propofol (5 mg·kg− 1·h− 1), sufentanil (0.01 µg·kg− 1·min− 1), and remimazolam tosilate (0.15 mg·kg− 1·h− 1) was administered. Intermittent intravenous bolus injection of rocuronium (0.15 mg/kg) was given to maintain muscle relaxation. Intraoperatively, the BIS value was maintained between 40 and 60, and vasoactive agents were used to keep the MAP fluctuation range within 20% of the baseline value. Nerve block technique Thirty minutes after anesthesia induction and prior to surgical incision, PSB combined with RSB was performed by an experienced anesthesiologist under ultrasound guidance, following the procedures below: ①PSB: The patient was placed in a supine position. A linear ultrasound probe was positioned 2 cm lateral to the sternum for sagittal scanning, enabling clear visualization of the pectoralis major muscle, internal intercostal muscle, costal cartilage, pleura, and lung tissue. The in-plane technique was utilized for needle insertion: costal cartilages were identified sequentially from the 2nd to the 6th rib, and blocks were administered at the levels of the 2nd, 4th, and 6th costal cartilages bilaterally. A 22G/4-inch puncture needle was advanced from caudal to cranial until the needle tip reached the surface of the costal cartilage. After confirming negative aspiration for blood and air, 5 mL of the corresponding local anesthetic was injected at each level (2nd, 4th, and 6th costal cartilages) on both sides, resulting in a total volume of 15 mL per side.②RSB: A 5–10 MHz linear ultrasound probe was placed 3 cm below the xiphoid process for transverse scanning to identify the rectus abdominis muscle, anterior rectus sheath, and posterior rectus sheath. Using the in-plane technique, the needle was advanced into the space between the rectus abdominis muscle and the posterior rectus sheath. Following negative aspiration for blood, 5 mL of the corresponding local anesthetic was injected on each side, with a total bilateral volume of 10 mL. For nerve blocks, group LB received a total volume of 40 mL liposomal bupivacaine injection (containing 266 mg bupivacaine), while group ROP received 40 mL of 0.375% ropivacaine injection. Outcomes Primary outcome Cumulative analgesic consumption at 12 h, 24 h, and 48 h after first awakening, calculated as morphine milligram equivalents (MMEs). Secondary outcome Postoperative endotracheal extubation time, drainage tube removal time, ICU length of stay (LOS), hospital LOS, incidence of nausea and vomiting, incidence of arrhythmia, post-extubation reintubation rate, and ICU readmission rate.Postoperative resting and ambulatory NRS points. Numeric Rating Scale (NRS) points at 1 and 3 months postoperatively; chronic postsurgical pain (CPSP) was defined as NRS ≥ 1 at 3 months. QoR-15 scale was administered 1 day preoperatively and 24 h, 48 h, 72 h post-extubation to assess recovery quality. Postoperative endotracheal extubation time, drainage tube removal time, ICU length of stay (LOS), hospital LOS, incidence of nausea and vomiting, incidence of arrhythmia, post-extubation reintubation rate, and ICU readmission rate. Postoperative endotracheal extubation time, drainage tube removal time, ICU length of stay (LOS), hospital LOS, incidence of nausea and vomiting, incidence of arrhythmia, post-extubation reintubation rate, and ICU readmission rate. Postoperative resting and ambulatory NRS points. Postoperative resting and ambulatory NRS points. Numeric Rating Scale (NRS) points at 1 and 3 months postoperatively; chronic postsurgical pain (CPSP) was defined as NRS ≥ 1 at 3 months. QoR-15 scale was administered 1 day preoperatively and 24 h, 48 h, 72 h post-extubation to assess recovery quality. Numeric Rating Scale (NRS) points at 1 and 3 months postoperatively; chronic postsurgical pain (CPSP) was defined as NRS ≥ 1 at 3 months. QoR-15 scale was administered 1 day preoperatively and 24 h, 48 h, 72 h post-extubation to assess recovery quality. Sample size calculation Pilot study results showed that the 24-hour MME consumption after first awakening was 60.46 ± 24.14 mg in the liposomal bupivacaine group (N = 10) and 69.04 ± 20.06 mg in the ropivacaine group (N = 10). Sample size was calculated using PASS 2021, with type I error rate α = 0.05 and power = 0.8. The minimum sample size required per group was 38 cases, and 45 cases were included in each group in this study. Statistical analysis Statistical analysis was performed using SPSS 26.0. The Shapiro-Wilk test was used to verify the normality of continuous data. Normally distributed data were expressed as mean ± standard deviation and analyzed by independent samples t-test; otherwise, data were presented as median (interquartile range) [M(P25, P75)] and analyzed using the Mann-Whitney U test. For comparisons of normally distributed continuous data before and after surgery, paired samples t-test was used; otherwise, paired samples Wilcoxon signed-rank test was adopted. Categorical data were expressed as frequencies and percentages (%) and analyzed by Chi-square test (χ² test) or Fisher’s exact test. For repeated measurement data, if the data were normally distributed and homogeneous in variance, Repeated Measures ANOVA was used. When the data were not normally distributed or had non-independence, Generalized Estimating Equations (GEE) were used for analysis. The test level was set at α = 0.05 with two-tailed test. Result A total of 90 patients undergoing elective open-heart surgery were enrolled from April 2024 to February 2025, with 45 patients in group LB and 45 patients in group ROP. Two patients in group LB were excluded due to surgical duration > 8 h, resulting in 88 patients included in the final analysis. The baseline characteristics of group LB and group ROP are shown in Table 1. No statistically significant differences were observed in continuous variables such as age, height, weight, and BMI between the two groups (P > 0.05). Table 1Comparison of baseline characteristicsCharacteristicsROP(N = 45)LB(N = 43)Z/χ2/t P Age [M (P₂₅, P₇₅), years]55.0(46.5,59.0)55.0(42,60.0)-0.0750.940Gender [n (%)]0.0310.859 Female27(60.0%)25(58.1%) Male18(40.0%)18(41.9%)Height[\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\overline{x}{\pm}s$$\end{document},cm]160.0 ± 7.6160.7 ± 8.1-0.3080.759Weight[\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\overline{x}{\pm}s$$\end{document}, kg]59.7 ± 11.759.0 ± 11.41.0710.287BMI[\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\overline{x}{\pm}s$$\end{document}, kg/m2]23.2 ± 3.722.7 ± 3.20.6940.489ASA[n(%)]0.0030.954 Ⅱ3(6.7%)3(7.0%) Ⅲ42(93.3%)40(93.0%)Cardiac function [n (%)]1.1500.563 Ⅱ1(2.2%)3(7.0%) Ⅲ43(95.6%)39(90.7%) Ⅳ1(2.2%)1(2.3%)Surgical type5.4100.116 Cardiac valve surgery38(84.5%)33(76.7%) Corrective surgery for congenital heart disease2(4.4%)0 Coronary artery surgery1(2.2%)6 Aorta - related surgery4(8.9%)4 Table 1Comparison of baseline characteristicsCharacteristicsROP(N = 45)LB(N = 43)Z/χ2/t P Age [M (P₂₅, P₇₅), years]55.0(46.5,59.0)55.0(42,60.0)-0.0750.940Gender [n (%)]0.0310.859 Female27(60.0%)25(58.1%) Male18(40.0%)18(41.9%)Height[\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\overline{x}{\pm}s$$\end{document},cm]160.0 ± 7.6160.7 ± 8.1-0.3080.759Weight[\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\overline{x}{\pm}s$$\end{document}, kg]59.7 ± 11.759.0 ± 11.41.0710.287BMI[\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\overline{x}{\pm}s$$\end{document}, kg/m2]23.2 ± 3.722.7 ± 3.20.6940.489ASA[n(%)]0.0030.954 Ⅱ3(6.7%)3(7.0%) Ⅲ42(93.3%)40(93.0%)Cardiac function [n (%)]1.1500.563 Ⅱ1(2.2%)3(7.0%) Ⅲ43(95.6%)39(90.7%) Ⅳ1(2.2%)1(2.3%)Surgical type5.4100.116 Cardiac valve surgery38(84.5%)33(76.7%) Corrective surgery for congenital heart disease2(4.4%)0 Coronary artery surgery1(2.2%)6 Aorta - related surgery4(8.9%)4 Comparison of baseline characteristics Primary outcome Results of the comparison of cumulative MME consumption between the two groups at different postoperative time points showed that there was no statistically significant difference in the cumulative MME consumption within 12 h after first postoperative awakening between the two groups (P > 0.05, Table 2). However, the cumulative MME consumption in group LB within 24 h and 48 h after first postoperative awakening was lower than that in group ROP, with statistically significant differences (P < 0.05). Table 2Postoperative cumulative morphine equivalent consumption[M(P25, P75), mg]TimeROP(N = 45)LB(N = 43)Z P Within 12 h after the first postoperative awakening38.40(30.40,48.00)40.50(32.80,47.10)-1.2750.202Within 24 h after the first postoperative awakening68.00(48.40,80.00)55.30(47.80,62.10)-2.8360.005Within 48 h after the first postoperative awakening86.00(63.40,119.60)76.30(68.80,83.10)-2.1510.031 Table 2Postoperative cumulative morphine equivalent consumption[M(P25, P75), mg]TimeROP(N = 45)LB(N = 43)Z P Within 12 h after the first postoperative awakening38.40(30.40,48.00)40.50(32.80,47.10)-1.2750.202Within 24 h after the first postoperative awakening68.00(48.40,80.00)55.30(47.80,62.10)-2.8360.005Within 48 h after the first postoperative awakening86.00(63.40,119.60)76.30(68.80,83.10)-2.1510.031 Postoperative cumulative morphine equivalent consumption[M(P25, P75), mg] Secondary outcome Concerning postoperative recovery indicators and adverse events (including postoperative endotracheal extubation time, drainage tube removal time, ICU LOS, hospital LOS, incidence of nausea and vomiting, incidence of arrhythmia, post-extubation reintubation rate, and ICU readmission rate), no statistically significant differences were found between the two groups in postoperative extubation time, ICU length of stay and other recovery indicators (P > 0.05, Table 3). Neither group experienced ICU readmission after discharge, and there were no statistically significant differences in the incidence of arrhythmia and post-extubation reintubation rate between the two groups. The sole statistically significant between-group difference was the incidence of nausea and vomiting, which was 16.3% in group LB and 2.2% in group ROP (P < 0.05) (Table 4). Table 3Comparison of postoperative recovery between the two groups [M(P25, P75)]ItemROP(N = 45)LB(N = 43)Z/t P Time to first postoperative awakening (h)1.5(1.25,1.9)1.5(1.3,1.65)-0.2560.798Postoperative endotracheal extubation time (h)21.0(17.0,36.0)21.5(15.0,27.35)-0.1880.851Postoperative drainage tube removal time (h)57.0(50.0,88.8)62.5(49.0,86.5)-0.2170.828ICU length of stay (h)38.5(27.0,69.3)42.5(26.3,60.5)-0.0210.983Hospital length of stay (d)13.0(11.0,18.5)14.0(12.0,16.5)-0.2720.785 Table 3Comparison of postoperative recovery between the two groups [M(P25, P75)]ItemROP(N = 45)LB(N = 43)Z/t P Time to first postoperative awakening (h)1.5(1.25,1.9)1.5(1.3,1.65)-0.2560.798Postoperative endotracheal extubation time (h)21.0(17.0,36.0)21.5(15.0,27.35)-0.1880.851Postoperative drainage tube removal time (h)57.0(50.0,88.8)62.5(49.0,86.5)-0.2170.828ICU length of stay (h)38.5(27.0,69.3)42.5(26.3,60.5)-0.0210.983Hospital length of stay (d)13.0(11.0,18.5)14.0(12.0,16.5)-0.2720.785 Comparison of postoperative recovery between the two groups [M(P25, P75)] Table 4Comparison of postoperative adverse reactions between the two groups [n(%)]GroupNausea and vomitingMalignant arrhythmiaReintubation post-extubationRe-admission after ICU dischargeROP(N = 45)1(2.2%)1 (2.2%)0 (0%)0 (0%)LB(N = 43)7(16.3%)1 (2.3%)1 (2.3%)0 (0%) χ 2 5.8180.001-- P 0.0280.9740.489- Table 4Comparison of postoperative adverse reactions between the two groups [n(%)]GroupNausea and vomitingMalignant arrhythmiaReintubation post-extubationRe-admission after ICU dischargeROP(N = 45)1(2.2%)1 (2.2%)0 (0%)0 (0%)LB(N = 43)7(16.3%)1 (2.3%)1 (2.3%)0 (0%) χ 2 5.8180.001-- P 0.0280.9740.489- Comparison of postoperative adverse reactions between the two groups [n(%)] As for postoperative resting and ambulatory NRS scores, there were no statistically significant differences in resting NRS scores between the two groups at all time points (P > 0.05, Table 5 ). For ambulatory NRS scores, those in group LB were lower than those in group ROP only at 4 and 12 h post-extubation (P < 0.05, Table 6), with no differences at other time points. In addition, the resting NRS scores of both groups showed a gradual increasing trend from 4 to 24 h post-extubation (Table 5), and the ambulatory NRS scores showed the same increasing trend (Table 6). Table 5Postoperative resting NRS of patients [M(P25, P75), points]TimeROP(N = 45)LB(N = 43)Z P At extubation completion0.00(0.00,1.00)0.00(0.00,1.00)-1.2950.1954 h post-extubation1.00(0.00,2.00)1.00(1.00,1.00)-0.8250.41012 h post-extubation1.00(1.00,2.00)1.00(1.00,1.00)-1.4040.16024 h post-extubation2.00(1.00,2.00)1.00(1.00,2.00)-1.3280.18448 h post-extubation2.00(1.00,2.00)1.00(1.00,2.00)-1.3490.177 Table 5Postoperative resting NRS of patients [M(P25, P75), points]TimeROP(N = 45)LB(N = 43)Z P At extubation completion0.00(0.00,1.00)0.00(0.00,1.00)-1.2950.1954 h post-extubation1.00(0.00,2.00)1.00(1.00,1.00)-0.8250.41012 h post-extubation1.00(1.00,2.00)1.00(1.00,1.00)-1.4040.16024 h post-extubation2.00(1.00,2.00)1.00(1.00,2.00)-1.3280.18448 h post-extubation2.00(1.00,2.00)1.00(1.00,2.00)-1.3490.177 Postoperative resting NRS of patients [M(P25, P75), points] Table 6Postoperative active NRS scores of patients [M(P25, P75), points]TimeROP(N = 45)LB(N = 43)Z P At extubation completion2.00(2.00,3.00)2.00(1.00,2.00)-1.5200.1284 h post-extubation2.00(2.00,3.00)2.00(2.00,2.00)-2.4830.01312 h post-extubation3.00(2.00,4.00)2.00(2.00,3.00)-3.1880.00124 h post-extubation4.00(2.00,4.00)3.00(3.00,3.5)-1.1030.27048 h post-extubation4.00(2.00,4.00)3.00(2.5,3.00)-1.6260.104 Table 6Postoperative active NRS scores of patients [M(P25, P75), points]TimeROP(N = 45)LB(N = 43)Z P At extubation completion2.00(2.00,3.00)2.00(1.00,2.00)-1.5200.1284 h post-extubation2.00(2.00,3.00)2.00(2.00,2.00)-2.4830.01312 h post-extubation3.00(2.00,4.00)2.00(2.00,3.00)-3.1880.00124 h post-extubation4.00(2.00,4.00)3.00(3.00,3.5)-1.1030.27048 h post-extubation4.00(2.00,4.00)3.00(2.5,3.00)-1.6260.104 Postoperative active NRS scores of patients [M(P25, P75), points] Regarding NRS scores at 1 and 3 months postoperatively, post-discharge NRS scores of groups ROP and LB showed no statistically significant differences at 1 and 3 months post-discharge between the two groups (P > 0.05) (Table 7); thus, the incidence of CPSP (defined as NRS ≥ 1 at 3 months) had no statistically significant difference between the two groups. For the QoR-15 questionnaire administered 1 day preoperatively and 24 h, 48 h, 72 h post-extubation to assess recovery quality, group LB scored significantly higher than group ROP at 24, 48 and 72 h post-extubation (P < 0.05, Table 8). Table 7NRS of two groups of patients after dischargeItemROP(N = 45)LB(N = 43)Z/χ2 P 1-month post-discharge NRS[ M(P25, P75), point]1.00(0.00,1.00)1.00(0.00,1.00)-0.3290.7423-month post-discharge NRS[ M(P25, P75), point]0.00(0.00,1.00)0.00(0.00,0.00)-0.3830.702CPSP[n(%)]14(31.1%)9(20.9%)1.1810.277 Table 7NRS of two groups of patients after dischargeItemROP(N = 45)LB(N = 43)Z/χ2 P 1-month post-discharge NRS[ M(P25, P75), point]1.00(0.00,1.00)1.00(0.00,1.00)-0.3290.7423-month post-discharge NRS[ M(P25, P75), point]0.00(0.00,1.00)0.00(0.00,0.00)-0.3830.702CPSP[n(%)]14(31.1%)9(20.9%)1.1810.277 NRS of two groups of patients after discharge 1-month post-discharge NRS [ M(P25, P75), point] 3-month post-discharge NRS [ M(P25, P75), point] Table 8Comparison of quality of recovery-15 score before and after surgery[M(P25, P75), \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\overline{x}{\pm}s$$\end{document}, points]TimeROP(N = 45)LB(N = 43)Z/t P 1 day before surgery133.0(126.0,135.0)133.0(126.0,135.0)-0.1380.89024 h post-extubation74.7 ± 9.8985.4 ± 11.78-4.624< 0.00148 h post-extubation86.8 ± 8.691.6 ± 10.4-2.3510.02172 h post-extubation100.0 ± 9.15107.1 ± 9.87-0.521< 0.001 Table 8Comparison of quality of recovery-15 score before and after surgery[M(P25, P75), \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\overline{x}{\pm}s$$\end{document}, points]TimeROP(N = 45)LB(N = 43)Z/t P 1 day before surgery133.0(126.0,135.0)133.0(126.0,135.0)-0.1380.89024 h post-extubation74.7 ± 9.8985.4 ± 11.78-4.624< 0.00148 h post-extubation86.8 ± 8.691.6 ± 10.4-2.3510.02172 h post-extubation100.0 ± 9.15107.1 ± 9.87-0.521< 0.001 Comparison of quality of recovery-15 score before and after surgery[M(P25, P75), \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\overline{x}{\pm}s$$\end{document}, points] Discussion Adequate pain management following open-heart surgery is critical for promoting rapid patient rehabilitation, as postoperative pain arises from a complex interplay of surgical trauma, nerve injury, visceral pain, drainage tube placement, sternal retraction, and reduced postoperative chest wall stability. Historically, opioids such as morphine and fentanyl have been the mainstay of perioperative analgesia, effectively alleviating moderate to severe pain [14]. However, their dose-dependent efficacy is accompanied by significant drawbacks: excessive doses may cause respiratory depression, prolonged mechanical ventilation, pulmonary complications, and gastrointestinal adverse effects, while insufficient doses fail to adequately control postoperative pain when used alone [14]. Thus, multimodal analgesia is now considered essential in clinical practice. This strategy integrates various analgesic techniques and drugs to simultaneously target multiple points within the pain pathway, enhancing overall pain control while reducing the side effects associated with reliance on any single agent. This approach facilitates faster postoperative recovery and improves patient well-being. For major surgical procedures involving significant tissue trauma, a multimodal approach typically combines regional nerve blocks with intravenous medications, including local anesthetics, opioids, anti‑inflammatory drugs (NSAIDs), and other adjuvants [15]. Regional nerve block analgesia, increasingly adopted in perioperative care for open‑heart surgery, inhibits nociceptive transmission directly within the surgical area, thereby lowering both pain intensity and opioid requirements [16]. Unlike systemic intravenous analgesia, this approach delivers targeted relief with minimal disturbance to overall physiological and circulatory function—a particular advantage in cardiac surgery, where preventing pain‑induced sympathetic activation is crucial for maintaining hemodynamic stability and postoperative safety. Liposomal bupivacaine and ropivacaine are pivotal agents for regional analgesia [17]. Liposomal bupivacaine achieves sustained analgesia via a unique multivesicular liposome formulation that enables a distinctive three-phase drug release profile, significantly extending the duration of action following a single administration [12]. Ropivacaine, another long-acting amide local anesthetic, is characterized by differential sensory-motor blockade, producing effective sensory blockade with minimal motor impairment, thereby facilitating early postoperative mobilization. This prospective randomized controlled trial was designed to directly compare the analgesic efficacy and safety profiles of these two agents when used in regional nerve blocks for patients undergoing median sternotomy open-heart surgery, aiming to address an evidence gap regarding their comparative impact on postoperative recovery. Our findings demonstrated that, compared with ropivacaine, liposomal bupivacaine administered in a parasternal combined rectus sheath block provided superior analgesic duration and reduced postoperative opioid consumption, though it was associated with a higher incidence of postoperative nausea and vomiting. Pain intensity was assessed using the NRS, a 10-cm horizontal line anchored at 0 (representing “no pain”) and 10 (representing “excruciating pain”), with categorized as mild (1–3), moderate (4–6), severe (7–9), or excruciating (10). Although the NRS is simple and intuitive for cognitively intact adults, it is limited by its subjective nature and inapplicability to patients with cognitive or communication impairments. No significant difference in cumulative morphine milligram equivalent consumption within 12 h of awakening was observed between groups (P > 0.05), suggesting similar early analgesic efficacy, likely because liposomal bupivacaine releases sufficient free drug to reach effective concentrations during this initial period. Both groups had low resting NRS scores at extubation, which may be attributed to high blood concentrations of ICU-administered analgesics (e.g., butorphanol, remifentanil) and residual local anesthetic effects. From 4 to 48 h post-extubation, the liposomal bupivacaine group exhibited lower and more concentrated median NRS scores, consistent with significantly reduced morphine equivalent consumption at 24 and 48 h post-awakening. This indicates reduced rescue analgesia needs and confirms its long-acting advantage. This prolonged effect is mediated by its unique three-phase release profile [13]. In contrast, ropivacaine is rapidly metabolized, with declining concentrations leading to weakened analgesia and consequently higher NRS scores. Residual intraoperative analgesic effects also influenced early pain perception: while initially masking differences between groups, their dissipation uncovered the sustained analgesic benefit of liposomal bupivacaine, whereas group ROP experienced pain escalation as ropivacaine efficacy diminished. No significant difference was observed in resting NRS scores between the groups. However, activity-related NRS scores differed significantly at 4 and 12 h post-extubation. Resting pain may be adequately controlled by baseline analgesic regimens, whereas activities such as coughing or turning exacerbate pain related to incision stretch. This dynamic underscores the clinical value of liposomal bupivacaine’s prolonged analgesic action. Patients in group ROP exhibited higher activity-related pain scores as the analgesic effect diminished during early mobilization. In contrast, group LB maintained consistently lower pain levels under the same conditions. The majority of median NRS scores across time points fell within the 1–3 range, reflecting overall effective pain management and the efficacy of the implemented analgesic protocol. Notably, the period of liposomal bupivacaine’s secondary drug release (approximately 12–36 h post-administration) corresponded with its superior NRS performance, confirming that its unique sustained-release profile directly contributes to its extended analgesic efficacy [13, 18]. Compared to group ROP, group LB demonstrated a significantly higher MAP at the initiation of surgery (P < 0.05). This hemodynamic difference is likely attributable to the distinct pharmacokinetic profiles of the two agents. Liposomal bupivacaine has a reported onset of action of 30–60 min [17]; therefore, its analgesic effect may not have been fully established at the time of skin incision and during the initial surgical phase. Inadequate analgesia in this critical period can activate the sympathetic nervous system, leading to vasoconstriction, tachycardia, and consequently elevated MAP. In contrast, ropivacaine, with its more rapid onset of 10–20 min, typically provides sufficient sensory blockade by the start of surgery, effectively blocking the pain-mediated sympathetic response and thereby maintaining greater hemodynamic stability—as reflected in the lower MAP observed in group ROP. This observation suggests that insufficient analgesic depth during initial surgical stimulus may induce a significant intraoperative stress response, which could subsequently influence postoperative pain perception and recovery dynamics. CPSP is a common, underrecognized complication of cardiac surgery. Current preventive strategies focus on the acute phase, but they may not sufficiently target core neuropathic mechanisms such as Nerve Growth Factor (NGF)/Tyrosine kinase-A (TrkA) pathway activation and glial-mediated neuroinflammation, which contribute to persistent pain [19, 20]. We hypothesized that by providing sustained blockade of peripheral nociceptive input, liposomal bupivacaine might mitigate these processes and thereby reduce the incidence of CPSP [21]. Although no significant differences in NRS scores or CPSP incidence (31.1% in group ROP vs. 20.0% in group LB) were observed at 1 and 3 months post-discharge, the observed trend toward lower incidence in group LB is noteworthy. The lack of statistical significance may be attributable to the study being underpowered for this secondary outcome, given the relatively small sample size and individual patient variability [22]. Postoperative recovery was assessed using the QoR-15 scale [23]. Group LB had significantly higher scores at 24 and 48 h postoperatively, suggesting that sustained analgesia reduced pain-related disruption of rest and facilitated physiological recovery, whereas ropivacaine’s shorter duration of action led to waning efficacy and increased pain perception in group ROP. No significant differences in tracheal extubation time, ICU stay, or hospital length of stay were found, though group LB showed a non-significant trend toward earlier drainage tube removal. This may be related to improved wound healing from enhanced mobility and reduced pain-induced circulatory fluctuations [24]. While not statistically significant, liposomal bupivacaine’s analgesic benefits may offer clinical value, particularly for frail patients, and warrant investigation in larger studies. Vital sign stability (MAP, HR, SpO₂) is critical for perioperative cardiac surgery safety. Most time points showed no significant group differences in these parameters. However, MAP was significantly higher in group LB at surgery initiation, reflecting liposomal bupivacaine’s slower onset as discussed previously. Group LB also had higher HR at surgery initiation, which may be attributed to delayed pain signal blockade, with subsequent stabilization following anesthetic or sedative adjustments. SpO₂ differed only at 48 h post-extubation, a finding that may relate to individual respiratory recovery patterns or preoperative lung function and requires further investigation. Intraoperative sufentanil doses were similar between groups. This is consistent with the anatomical understanding that parasternal block primarily targets T2-T6 intercostal nerve anterior branches for chest wall analgesia but does not cover visceral pain from cardiac surfaces or intracardiac manipulation [25], indicating potential for optimizing regional block regimens to further reduce intraoperative opioid use. Safety data showed a significantly higher incidence of nausea and vomiting in group LB (P < 0.05), consistent with reports listing gastrointestinal adverse effects as common (> 10%) for liposomal bupivacaine. However, the literature is conflicting; some studies, such as those in mastectomy patients, have reported that ultrasound-guided thoracic nerve block with liposomal bupivacaine reduced opioid consumption and subsequent nausea/vomiting [18]. These discrepancies may relate to differences in administration technique, block site, surgical type, or patient populations. The sustained-release formulation could lead to drug accumulation and concentration fluctuations, contributing to adverse effects. Surgical stress, concomitant anesthetic/antiemetic use, and patient factors (e.g., age, gender, comorbidities) are also important confounders. Larger, more rigorously controlled studies are needed to clarify these relationships. Overall, both agents demonstrated a favorable safety profile in this study: no ICU readmissions occurred, and only one case of reintubation was reported in group LB. Previous studies have shown conflicting results. For instance, while one study found that liposomal bupivacaine maintained low pain scores long-term in thoracotomy [26], a meta-analysis by Kendall et al. [18] (9 trials, 779 patients) found no significant difference in 24/48-hour resting NRS scores compared to conventional local anesthetics. Similarly, Shih et al. [27] reported no reduction in 72-hour opioid use with preoperative parasternal block in cardiac surgery, a finding potentially attributable to differences in drug concentration, volume, or operator technique. In our study, the distinct pharmacokinetic profiles—liposomal bupivacaine’s sustained release and ropivacaine’s rapid metabolism—likely drove the observed differences in pain scores and analgesic requirements. Despite a final sample size slightly smaller than planned in group LB (43 vs. a preset 45, due to two prolonged surgeries), the sample still exceeded the minimum 38 cases required for adequate statistical power, and no data distribution abnormalities were noted, supporting the credibility of our findings. This study has limitations: small sample size, unexamined effects of drug concentration/dosage, and lack of long-term CPSP follow-up. Future research should expand sample size, optimize regional block regimens with ultrasound guidance, and extend follow-up to validate liposomal bupivacaine’s value. In conclusion, liposomal bupivacaine offers long-acting analgesia, reduces postoperative opioid use, and improves recovery quality in median sternotomy open-heart surgery, but requires attention to increased nausea and vomiting. Clinical selection should balance efficacy and safety based on individual patient characteristics to facilitate rapid rehabilitation. Conclusion For patients undergoing open-heart surgery, parasternal combined rectus sheath block with liposomal bupivacaine provides distinct clinical advantages over a ropivacaine-based regimen. These benefits include a significant reduction in postoperative analgesic requirements, improved quality of recovery, and superior analgesic efficacy in the early postoperative period. It should be noted, however, that the liposomal bupivacaine group was associated with a relatively higher incidence of postoperative nausea and vomiting (PONV). In summary, these findings support the incorporation of liposomal bupivacaine into multimodal perioperative analgesia protocols for open-heart surgery, with concurrent prophylactic measures recommended to mitigate PONV risk. Supplementary Information Supplementary Material 1. Supplementary Material 1.